These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 28729205

  • 1. Antimicrobial susceptibility of Clostridium difficile isolates in Israel.
    Tkhawkho L, Nitzan O, Pastukh N, Brodsky D, Jackson K, Peretz A.
    J Glob Antimicrob Resist; 2017 Sep; 10():161-164. PubMed ID: 28729205
    [Abstract] [Full Text] [Related]

  • 2. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
    Cheng JW, Yang QW, Xiao M, Yu SY, Zhou ML, Kudinha T, Kong F, Liao JW, Xu YC.
    J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
    [Abstract] [Full Text] [Related]

  • 3. A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole.
    Adler A, Miller-Roll T, Bradenstein R, Block C, Mendelson B, Parizade M, Paitan Y, Schwartz D, Peled N, Carmeli Y, Schwaber MJ.
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):21-4. PubMed ID: 26116225
    [Abstract] [Full Text] [Related]

  • 4. The emergence of metronidazole and vancomycin reduced susceptibility in Clostridium difficile isolates in Iran.
    Kouhsari E, Douraghi M, Krutova M, Fakhre Yaseri H, Talebi M, Baseri Z, Moqarabzadeh V, Sholeh M, Amirmozafari N.
    J Glob Antimicrob Resist; 2019 Sep; 18():28-33. PubMed ID: 30703583
    [Abstract] [Full Text] [Related]

  • 5. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
    Poilane I, Fantinato C, Cruaud P, Collignon A.
    Pathol Biol (Paris); 2008 Sep; 56(7-8):412-6. PubMed ID: 18842360
    [Abstract] [Full Text] [Related]

  • 6. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from hospitals during a 4-year period in China.
    Chen YB, Gu SL, Shen P, Lv T, Fang YH, Tang LL, Li LJ.
    J Med Microbiol; 2018 Jan; 67(1):52-59. PubMed ID: 29160203
    [Abstract] [Full Text] [Related]

  • 7. Changes in Clostridium (Clostridioides) difficile PCR-Ribotype Distribution and Antimicrobial Resistance in a German Tertiary Care Hospital Over the Last 10 Years.
    Piepenbrock E, Stelzer Y, Berger F, Jazmati N.
    Curr Microbiol; 2019 Apr; 76(4):520-526. PubMed ID: 30805700
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
    Reigadas E, Alcalá L, Marín M, Pelaéz T, Martin A, Iglesias C, Bouza E.
    J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
    [Abstract] [Full Text] [Related]

  • 9. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.
    Freeman J, Vernon J, Pilling S, Morris K, Nicholson S, Shearman S, Longshaw C, Wilcox MH, Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes Study Group.
    Clin Microbiol Infect; 2018 Jul; 24(7):724-731. PubMed ID: 29066403
    [Abstract] [Full Text] [Related]

  • 10. Routine disc diffusion antimicrobial susceptibility testing of Clostridium difficile and association with PCR ribotype 027.
    Holt HM, Danielsen TK, Justesen US.
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2243-6. PubMed ID: 26319148
    [Abstract] [Full Text] [Related]

  • 11. Molecular characterization, toxin detection and resistance testing of human clinical Clostridium difficile isolates from Lebanon.
    Berger FK, Rasheed SS, Araj GF, Mahfouz R, Rimmani HH, Karaoui WR, Sharara AI, Dbaibo G, Becker SL, von Müller L, Bischoff M, Matar GM, Gärtner B.
    Int J Med Microbiol; 2018 Apr; 308(3):358-363. PubMed ID: 29478838
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012.
    Lachowicz D, Pituch H, Obuch-Woszczatyński P.
    Anaerobe; 2015 Feb; 31():37-41. PubMed ID: 25242196
    [Abstract] [Full Text] [Related]

  • 13. Highly antibiotic-resistant Clostridium difficile isolates from Iranian patients.
    Baghani A, Ghourchian S, Aliramezani A, Yaseri M, Mesdaghinia A, Douraghi M.
    J Appl Microbiol; 2018 Nov; 125(5):1518-1525. PubMed ID: 29957893
    [Abstract] [Full Text] [Related]

  • 14. Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis.
    Nyc O, Tejkalova R, Kriz Z, Ruzicka F, Kubicek L, Matejkova J, Kuijper E, Krutova M.
    Microb Drug Resist; 2017 Jul; 23(5):609-615. PubMed ID: 27860531
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB, Bauer MP, Sanders IM, Wilcox MH, Kuijper EJ, ECDIS Study Group.
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [Abstract] [Full Text] [Related]

  • 16. Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.
    Peretz A, Tkhawkho L, Pastukh N, Brodsky D, Halevi CN, Nitzan O.
    BMC Infect Dis; 2016 Jun 22; 16():309. PubMed ID: 27334992
    [Abstract] [Full Text] [Related]

  • 17. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM, Babakhani F, Goldstein EJ, Nagaro K, Sambol S, Sears P, Shue YK, Gerding DN.
    Anaerobe; 2009 Dec 22; 15(6):234-6. PubMed ID: 19755166
    [Abstract] [Full Text] [Related]

  • 18. The emergence of Clostridium difficile ribotypes 027 and 176 with a predominance of the Clostridium difficile ribotype 001 recognized in Slovakia following the European standardized Clostridium difficile infection surveillance of 2016.
    Novakova E, Stefkovicova M, Kopilec MG, Novak M, Kotlebova N, Kuijper E, Krutova M.
    Int J Infect Dis; 2020 Jan 22; 90():111-115. PubMed ID: 31707136
    [Abstract] [Full Text] [Related]

  • 19. Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.
    Kociolek LK, Gerding DN, Osmolski JR, Patel SJ, Snydman DR, McDermott LA, Hecht DW.
    Antimicrob Agents Chemother; 2016 Aug 22; 60(8):4896-900. PubMed ID: 27270275
    [Abstract] [Full Text] [Related]

  • 20. Molecular types and antimicrobial susceptibility patterns of Clostridium difficile isolates in different epidemiological settings in a tertiary care center in Israel.
    Miller-Roll T, Na'amnih W, Cohen D, Carmeli Y, Adler A.
    Diagn Microbiol Infect Dis; 2016 Dec 22; 86(4):450-454. PubMed ID: 27638350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.